ATE417613T1 - Substituierte chinoloncarbonsäuren, ihre derivate,wirkungsort und anwendungen - Google Patents
Substituierte chinoloncarbonsäuren, ihre derivate,wirkungsort und anwendungenInfo
- Publication number
- ATE417613T1 ATE417613T1 AT03726824T AT03726824T ATE417613T1 AT E417613 T1 ATE417613 T1 AT E417613T1 AT 03726824 T AT03726824 T AT 03726824T AT 03726824 T AT03726824 T AT 03726824T AT E417613 T1 ATE417613 T1 AT E417613T1
- Authority
- AT
- Austria
- Prior art keywords
- derivatives
- carboxylic acids
- substituted
- sub
- site
- Prior art date
Links
- 150000001735 carboxylic acids Chemical class 0.000 title 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 8
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 4
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 quinolone carboxylic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38064102P | 2002-05-14 | 2002-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE417613T1 true ATE417613T1 (de) | 2009-01-15 |
Family
ID=29549994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03726824T ATE417613T1 (de) | 2002-05-14 | 2003-05-12 | Substituierte chinoloncarbonsäuren, ihre derivate,wirkungsort und anwendungen |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7355047B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1503759B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4532263B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040107525A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1652784A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE417613T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003229043B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0309965A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2484308A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60325347D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1503759T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2319176T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL164734A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04011156A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ536061A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003097564A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040107525A (ko) * | 2002-05-14 | 2004-12-20 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도 |
| US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| DE102004004971B3 (de) * | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel |
| AU2005240657A1 (en) * | 2004-05-06 | 2005-11-17 | The Regents Of The University Of California | Substituted enaminones, their derivatives and uses thereof |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| BR122018075478B8 (pt) | 2004-06-24 | 2023-10-31 | Vertex Pharma | moduladores de transportadores de cassete de ligação de atp |
| JP4796622B2 (ja) * | 2005-04-11 | 2011-10-19 | エフ．ホフマン−ラ ロシュ アーゲー | （３，４−ジヒドロ−キナゾリン−２−イル）−インダン−１−イル−アミン |
| AU2006243244A1 (en) * | 2005-05-04 | 2006-11-09 | F. Hoffmann-La Roche Ag | (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-HT receptor |
| AU2006322045A1 (en) * | 2005-12-05 | 2007-06-14 | Merck & Co., Inc. | Quinolone M1 receptor positive allosteric modulators |
| EP1979367A2 (en) * | 2005-12-24 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Quinolin-4-one derivatives as modulators of abc transporters |
| HUE032813T2 (en) | 2005-12-28 | 2017-11-28 | Vertex Pharma | Solid forms of N- [2,4-bis (1,1-dimethyl ethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2013182B1 (en) * | 2006-03-13 | 2013-09-04 | Kyorin Pharmaceutical Co., Ltd. | Aminoquinolones as gsk-3 inhibitors |
| CA2660421A1 (en) * | 2006-08-10 | 2008-02-14 | Ferrer Internacional S.A. | 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions |
| EP1886996A1 (en) * | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| NZ576036A (en) | 2006-10-16 | 2010-10-29 | Bionomics Ltd | Naphthyridine containing compounds for treating anxiety disorders |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| WO2009040377A2 (en) * | 2007-09-27 | 2009-04-02 | Ge Healthcare Limited | Imaging agents |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| JP2012506857A (ja) * | 2008-10-23 | 2012-03-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合複素環式ｍ１受容体ポジティブアロステリック調節因子 |
| HUE035160T2 (en) | 2009-03-20 | 2018-05-02 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US20120093917A1 (en) * | 2009-04-02 | 2012-04-19 | Robert Hromas | Metnase and intnase inhibitors and their use in treating cancer |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CA2828780A1 (en) | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
| AU2012222869B2 (en) * | 2011-03-02 | 2015-08-13 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
| US9133188B2 (en) | 2011-05-12 | 2015-09-15 | Bionomics Limited | Methods for preparing naphthyridines |
| CA2865519C (en) | 2012-02-27 | 2018-01-02 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| CN107501107A (zh) * | 2017-09-26 | 2017-12-22 | 兰亚朝 | 喹诺酮药物的中间体合成方法 |
| CN111269131B (zh) * | 2020-03-12 | 2021-12-28 | 江苏飞宇医药科技股份有限公司 | 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
| JPS5715760B2 (cg-RX-API-DMAC7.html) * | 1974-06-11 | 1982-04-01 | ||
| US4390541A (en) | 1980-12-19 | 1983-06-28 | Lilly Industries Limited | Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease |
| US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| US6413956B1 (en) * | 1999-05-06 | 2002-07-02 | Neurogen Corporation | Substituted 4-oxo-quinoline-3-carboxamides |
| GB0127349D0 (en) * | 2001-11-14 | 2002-01-02 | Glaxo Group Ltd | Macrolides |
| KR20040107525A (ko) * | 2002-05-14 | 2004-12-20 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 치환된 퀴놀론 카르복실산, 이들의 유도체, 그의 작용부위 및 용도 |
-
2003
- 2003-05-12 KR KR10-2004-7018340A patent/KR20040107525A/ko not_active Ceased
- 2003-05-12 CA CA002484308A patent/CA2484308A1/en not_active Abandoned
- 2003-05-12 ES ES03726824T patent/ES2319176T3/es not_active Expired - Lifetime
- 2003-05-12 MX MXPA04011156A patent/MXPA04011156A/es active IP Right Grant
- 2003-05-12 BR BR0309965-2A patent/BR0309965A/pt not_active IP Right Cessation
- 2003-05-12 DK DK03726824T patent/DK1503759T3/da active
- 2003-05-12 JP JP2004505299A patent/JP4532263B2/ja not_active Expired - Fee Related
- 2003-05-12 AT AT03726824T patent/ATE417613T1/de not_active IP Right Cessation
- 2003-05-12 CN CNA03810816XA patent/CN1652784A/zh active Pending
- 2003-05-12 EP EP03726824A patent/EP1503759B1/en not_active Expired - Lifetime
- 2003-05-12 WO PCT/US2003/014948 patent/WO2003097564A2/en not_active Ceased
- 2003-05-12 US US10/514,808 patent/US7355047B2/en not_active Expired - Fee Related
- 2003-05-12 DE DE60325347T patent/DE60325347D1/de not_active Expired - Lifetime
- 2003-05-12 AU AU2003229043A patent/AU2003229043B2/en not_active Ceased
- 2003-05-12 NZ NZ536061A patent/NZ536061A/en unknown
-
2004
- 2004-10-20 IL IL16473404A patent/IL164734A0/xx unknown
-
2008
- 2008-02-15 US US12/032,403 patent/US20080176897A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0309965A (pt) | 2005-03-01 |
| US7355047B2 (en) | 2008-04-08 |
| EP1503759A2 (en) | 2005-02-09 |
| CA2484308A1 (en) | 2003-11-27 |
| US20080176897A1 (en) | 2008-07-24 |
| HK1072905A1 (en) | 2005-09-16 |
| IL164734A0 (en) | 2005-12-18 |
| CN1652784A (zh) | 2005-08-10 |
| AU2003229043A1 (en) | 2003-12-02 |
| EP1503759B1 (en) | 2008-12-17 |
| JP2005535592A (ja) | 2005-11-24 |
| AU2003229043B2 (en) | 2008-12-04 |
| KR20040107525A (ko) | 2004-12-20 |
| MXPA04011156A (es) | 2005-02-17 |
| DE60325347D1 (de) | 2009-01-29 |
| NZ536061A (en) | 2008-09-26 |
| DK1503759T3 (da) | 2009-04-14 |
| JP4532263B2 (ja) | 2010-08-25 |
| WO2003097564A3 (en) | 2004-02-26 |
| EP1503759A4 (en) | 2006-02-15 |
| ES2319176T3 (es) | 2009-05-05 |
| WO2003097564A2 (en) | 2003-11-27 |
| US20060178516A1 (en) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE417613T1 (de) | Substituierte chinoloncarbonsäuren, ihre derivate,wirkungsort und anwendungen | |
| CY1120241T1 (el) | Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου | |
| DK1641764T3 (da) | P38-kinasehæmmere på grundlag af 5-leddede heterocykliske forbindelser | |
| MX2007003335A (es) | Acidos aceticos de bencimidazol que muestran antagonismo de receptor crth2 y usos de los mismos. | |
| DE60215652D1 (de) | Aromatische hydroxamsäurederivate, die sich als hdac inhibitoren eignen | |
| EP1391201A4 (en) | MEDICAL COMPOSITIONS | |
| EP2234963A4 (en) | LEVODOPA FORMULATIONS WITH CONTROLLED RELEASE AND ITS USE | |
| EA200100958A1 (ru) | Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2 | |
| EA200970190A1 (ru) | Соединения индола | |
| DK1311256T3 (da) | Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser | |
| CY1108011T1 (el) | Συνδυασμος παρεμποδιστου nsaid και pde4 | |
| DE602005013417D1 (de) | (biphenyl)carbonsäuren und derivate davon | |
| CY1107688T1 (el) | Δικυκλικες ενωσεις πυρρολιδινης | |
| NO20072767L (no) | Gabapentin prodrug vedvarende frigivelse orale doseringsformer | |
| DE602005025672D1 (de) | Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren | |
| WO2004031374A3 (en) | Secondary binding site of dipeptidyl peptidase iv (dp iv) | |
| UY27618A1 (es) | Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico | |
| DK0966424T3 (da) | Aminobenzophenoner som inhibitorer for interleukin og TNF | |
| NO20056161L (no) | Formuleringer for behandling av artrittilstander | |
| UA85711C2 (ru) | Замещенные енаминоны, их производные и их применение | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| ITMC20010029U1 (it) | Placca chirurgica anti-trauma per il fissaggio di monconi mandibiolari | |
| ATE466858T1 (de) | 3-arylisoxazol-4-carbonylbenzofuranderivative | |
| DE60216083D1 (de) | (OXOPYRAZOLOi1,5AöPYRIMIDIN-2-YL) ALKYLCARBONSÄUREAMIDE | |
| NO20014059L (no) | Krystallmodifikasjon D av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo-/4.3.0/-nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1503759 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |